- Home
- CNTG
CNTG
Centogene N.V.
as 07-26-2024 4:00pm EST
Centogene NV is a United States-based company engaged in data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. The company operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its diagnostics segment provides targeted genetic sequencing and diagnostics services to patients. Its geographic regions are Europe, the Middle East, North America, and Latin America.
| Founded: | 2006 | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | 11.8M | IPO Year: | 2019 |
| Target Price: | N/A | AVG Volume (30 days): | 46.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.33 - $1.53 | Next Earning Date: | 09-05-2024 |
| Revenue: | $53,928,889 | Revenue Growth: | 2.24% |
| Revenue Growth (this year): | 25.04% | Revenue Growth (next year): | N/A |
Latest Centogene N.V. News
CNTG Breaking Stock News: Dive into CNTG Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
GlobeNewswire
2 months ago
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
MT Newswires
2 months ago
Top Premarket Gainers
GlobeNewswire
2 months ago
CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights
GlobeNewswire
2 months ago
CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position
MT Newswires
2 months ago
Centogene, Evotec Discover New Molecule for Potential Gaucher Disease Treatment
GlobeNewswire
2 months ago
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
GlobeNewswire
3 months ago
CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
Compare CNTG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CNTG Centogene N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.